OBJECTIVE: To investigate the therapeutic effect of the herbal medication Xiao Pi-II on the symptoms and gastric motility of patients with functional dysepsia (FD). METHODS: A total of 180 FD patients were divided ran...OBJECTIVE: To investigate the therapeutic effect of the herbal medication Xiao Pi-II on the symptoms and gastric motility of patients with functional dysepsia (FD). METHODS: A total of 180 FD patients were divided randomly and equally into Xiao Pi-II and mosapride groups. The two groups were treated with Xiao Pi-II (100 mL, t.d.s., ante cibum) and mosapride (5 mg, t. d.s., ante cibum) for 2 weeks. Before treatment and 3 days after all medication was stopped, patients responded to a questionnaire evaluating gastrointestinal symptoms and were assessed with abdominal three dimensional ultrasonography (3D-US) for gastric motility. RESULTS: Gastrointestinal symptoms (especially bloating, post-prandial fullness and eructation) were improved significantly in FD patients treated with Xiao Pi-II (P<0.05, P<0.05, and P<0.05), but no significant difference was found in the mosapride group (P>0.05). The effective rates in the Xiao Pi-II and mosapride group were 86.7% and 60.0%, respectively (P<0.05). The gastric liquid emptyingrate (GLER) in the Xiao Pi-II group showed a significant increase (P<0.01) after 2 weeks of treatment but there was no significant change (P>0.05) of GLER in the mosapride group. CONCLUSION: Compared with mosapride, Xiao Pi-II improved symptoms and GLER significantly in FD patients with delayed gastric emptying.展开更多
文摘OBJECTIVE: To investigate the therapeutic effect of the herbal medication Xiao Pi-II on the symptoms and gastric motility of patients with functional dysepsia (FD). METHODS: A total of 180 FD patients were divided randomly and equally into Xiao Pi-II and mosapride groups. The two groups were treated with Xiao Pi-II (100 mL, t.d.s., ante cibum) and mosapride (5 mg, t. d.s., ante cibum) for 2 weeks. Before treatment and 3 days after all medication was stopped, patients responded to a questionnaire evaluating gastrointestinal symptoms and were assessed with abdominal three dimensional ultrasonography (3D-US) for gastric motility. RESULTS: Gastrointestinal symptoms (especially bloating, post-prandial fullness and eructation) were improved significantly in FD patients treated with Xiao Pi-II (P<0.05, P<0.05, and P<0.05), but no significant difference was found in the mosapride group (P>0.05). The effective rates in the Xiao Pi-II and mosapride group were 86.7% and 60.0%, respectively (P<0.05). The gastric liquid emptyingrate (GLER) in the Xiao Pi-II group showed a significant increase (P<0.01) after 2 weeks of treatment but there was no significant change (P>0.05) of GLER in the mosapride group. CONCLUSION: Compared with mosapride, Xiao Pi-II improved symptoms and GLER significantly in FD patients with delayed gastric emptying.
